Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-03-2022 | Liposarcoma | Original Article – Cancer Research

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment

Authors: Christian Vay, Philipp M. Schlünder, Levent Dizdar, Irene Esposito, Markus P. H. Ghadimi, Wolfram T. Knoefel, Andreas Krieg

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2022

Abstract

Purpose

Liposarcoma (LPS) represent the largest group of malignant soft tissue tumours comprising a heterogeneous group of subtypes in which the degrees of chemoresistance and radiosensitivity strongly vary. Consequently, it is of utmost interest to establish novel therapeutic regimens based on molecular targets.

Methods

Immunohistochemical staining of survivin was performed in tissue microarrays comprising 49 primary LPS specimens. LPS cell lines were treated with survivin antagonist YM155 and doxorubicin or etoposide alone as well as in combination. Changes in cell viability were investigated and the synergistic effect of a combined therapy analysed.

Results

Immunohistochemistry revealed an abundant expression of survivin in LPS that significantly concurred with less-differentiated tumour subtypes and grading. In vitro, we demonstrated the impact of the survivin inhibitor YM155 on dedifferentiated LPS (DDLPS) and, even more imposing, pleomorphic LPS (PLS) tumour cell viability with a strong induction of apoptosis. A combined treatment of doxorubicin or etoposide with YM155 augmented the cytotoxic effects on DDLPS and PLS cells.

Conclusion

These findings support the significant role of survivin in the oncogenesis and progression of LPS subtypes providing a rationale to target survivin in eligible in-vivo models and to pioneer clinical applications of survivin-specific substances unfolding their therapeutic potential in LPS patients prospectively.

Available only for authorised users

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921. https://doi.org/10.1038/nm0897-917CrossRefPubMed

Anaya DA, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, Lev DC, Pollock RE (2009) Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg 249:137–142. https://doi.org/10.1097/SLA.0b013e3181928f2fCrossRefPubMed

Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715–721. https://doi.org/10.1038/ng.619CrossRefPubMedPubMedCentral

Brany D, Dvorska D, Slavik P, Skolka R, Adamkov M (2017) Survivin and gynaecological tumours. Pathol Res Pract 213:295–300. https://doi.org/10.1016/j.prp.2017.02.009CrossRefPubMed

Byun SS, Yeo WG, Lee SE, Lee E (2007) Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 69:34–37. https://doi.org/10.1016/j.urology.2006.09.024CrossRefPubMed

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, Li F (2012) Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3:179–197PubMedPubMedCentral

Crago AM, Brennan MF (2015) Principles in management of soft tissue sarcoma. Adv Surg 49:107–122. https://doi.org/10.1016/j.yasu.2015.04.002CrossRefPubMedPubMedCentral

Crago AM, Dickson MA (2016) Liposarcoma: multimodality management and future targeted therapies. Surg Oncol Clin N Am 25:761–773. https://doi.org/10.1016/j.soc.2016.05.007CrossRefPubMedPubMedCentral

Crago AM, Socci ND, DeCarolis P, O’Connor R, Taylor BS, Qin LX, Antonescu CR, Singer S (2012) Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res 18:1334–1340. https://doi.org/10.1158/1078-0432.CCR-11-2820CrossRefPubMedPubMedCentral

Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S (2006) Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 244:381–391. https://doi.org/10.1097/01.sla.0000234795.98607.00CrossRefPubMedPubMedCentral

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovee J (2017) High-throughput screening of myxoid liposarcoma cell lines: survivin is essential for tumor growth. Transl Oncol 10:546–554. https://doi.org/10.1016/j.tranon.2017.05.007CrossRefPubMedPubMedCentral

Dizdar L, Oesterwind KA, Riemer JC, Werner TA, Mersch S, Mohlendick B, Schutte SC, Verde PE, Raba K, Topp SA, Stoecklein NH, Esposito I, Knoefel WT, Krieg A (2017a) Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia. Oncotarget 8:8369–8382. https://doi.org/10.18632/oncotarget.14207CrossRefPubMed

Dizdar L, Tomczak M, Werner TA, Safi SA, Riemer JC, Verde PE, Stoecklein NH, Knoefel WT, Krieg A (2017b) Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas. Oncol Lett 14:6847–6856. https://doi.org/10.3892/ol.2017.6999CrossRefPubMedPubMedCentral

Dizdar L, Junemann LM, Werner TA, Verde PE, Baldus SE, Stoecklein NH, Knoefel WT, Krieg A (2018) Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. Oncol Lett 15:3779–3789. https://doi.org/10.3892/ol.2018.7755CrossRefPubMedPubMedCentral

Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF, Singer S (2004) The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240:686–695. https://doi.org/10.1097/01.sla.0000141710.74073.0dCrossRefPubMedPubMedCentral

Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D (2011) Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer 117:5359–5369. https://doi.org/10.1002/cncr.26195CrossRefPubMed

Ghadimi MP, Young ED, Belousov R, Zhang Y, Lopez G, Lusby K, Kivlin C, Demicco EG, Creighton CJ, Lazar AJ, Pollock RE, Lev D (2012) Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res 18:2545–2557. https://doi.org/10.1158/1078-0432.CCR-11-2592CrossRefPubMedPubMedCentral

Guo H, Wang Y, Song T, Xin T, Zheng Z, Zhong P, Zhang X (2015) Silencing of survivin using YM155 inhibits invasion and suppresses proliferation in glioma cells. Cell Biochem Biophys 71:587–593. https://doi.org/10.1007/s12013-014-0238-4CrossRefPubMed

Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA, Azorsa DO (2013) BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer 60:35–40. https://doi.org/10.1002/pbc.24290CrossRefPubMed

Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E, Duffaud F, Patrikidou A, Lortal B, Le Cesne A, Blay JY, Maki RG, Schwartz GK, Antonescu CR, Singer S, Coindre JM, Bui B (2012) Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 23:1601–1607. https://doi.org/10.1093/annonc/mdr485CrossRefPubMed

Kanwar JR, Kamalapuram SK, Kanwar RK (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 33:765–789. https://doi.org/10.1002/med.21264CrossRefPubMed

Kappler M, Kotzsch M, Bartel F, Fussel S, Lautenschlager C, Schmidt U, Wurl P, Bache M, Schmidt H, Taubert H, Meye A (2003) Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 9:1098–1104PubMed

Knebel C, Lenze U, Pohlig F, Lenze F, Harrasser N, Suren C, Breitenbach J, Rechl H, von Eisenhart-Rothe R, Muhlhofer HML (2017) Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years. BMC Cancer 17:410. https://doi.org/10.1186/s12885-017-3398-yCrossRefPubMedPubMedCentral

Koike H, Nitta T, Sekine Y, Arai S, Furuya Y, Nomura M, Matsui H, Shibata Y, Ito K, Oyama T, Suzuki K (2014) YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol 140:1705–1713. https://doi.org/10.1007/s00432-014-1734-zCrossRefPubMed

Kooby DA, Antonescu CR, Brennan MF, Singer S (2004) Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol 11:78–84. https://doi.org/10.1007/BF02524350CrossRefPubMed

Krieg A, Baseras B, Tomczak M, Verde PE, Stoecklein NH, Knoefel WT (2013a) Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis. Mol Biol Rep 40:5501–5511. https://doi.org/10.1007/s11033-013-2650-zCrossRefPubMed

Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT (2013b) Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS ONE 8:e65338. https://doi.org/10.1371/journal.pone.0065338CrossRefPubMedPubMedCentral

LaPensee EW, Reddy SP, Hugo ER, Schwemberger SJ, Ben-Jonathan N (2007) LS14 cells: a model for chemoresistance in liposarcoma. Cancer Biol Ther 6:519–524. https://doi.org/10.4161/cbt.6.4.3816CrossRefPubMed

Lee AT, Pollack SM, Huang P, Jones RL (2017) Phase III soft tissue sarcoma trials: success or failure? Curr Treat Options Oncol 18:19. https://doi.org/10.1007/s11864-017-0457-1CrossRefPubMedPubMedCentral

Lee ATJ, Thway K, Huang PH, Jones RL (2018) Clinical and molecular spectrum of liposarcoma. J Clin Oncol 36:151–159. https://doi.org/10.1200/JCO.2017.74.9598CrossRefPubMed

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262CrossRefPubMed

Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, Lazar AJ, Hunt KK, Anderson ML, Creighton CJ, Lev D, Pollock RE (2013) Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution’s experience. Ann Surg Oncol 20:2364–2372. https://doi.org/10.1245/s10434-012-2834-0CrossRefPubMedPubMedCentral

Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30–36. https://doi.org/10.1002/ijc.10450CrossRefPubMed

McKenzie JA, Grossman D (2012) Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 32:397–404PubMed

Mersch S, Riemer JC, Schlunder PM, Ghadimi MP, Ashmawy H, Mohlendick B, Topp SA, Arent T, Kropil P, Stoecklein NH, Gabbert HE, Knoefel WT, Krieg A (2016) Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma. Tumour Biol 37:2341–2351. https://doi.org/10.1007/s13277-015-4050-6CrossRefPubMed

Packeisen J, Korsching E, Herbst H, Boecker W, Buerger H (2003) Demystified...tissue microarray technology. Mol Pathol 56:198–204. https://doi.org/10.1136/mp.56.4.198CrossRefPubMedPubMedCentral

Park JO, Qin LX, Prete FP, Antonescu C, Brennan MF, Singer S (2009) Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg 250:977–982. https://doi.org/10.1097/sla.0b013e3181b2468bCrossRefPubMed

Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS (1994) Myxoid liposarcoma. Experience with chemotherapy. Cancer 74:1265–1269. https://doi.org/10.1002/1097-0142(19940815)74:4%3c1265::aid-cncr2820740414%3e3.0.co;2-xCrossRefPubMed

Peery RC, Liu JY, Zhang JT (2017) Targeting survivin for therapeutic discovery: past, present, and future promises. Drug Discov Today 22:1466–1477. https://doi.org/10.1016/j.drudis.2017.05.009CrossRefPubMed

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986–1993. https://doi.org/10.1373/clinchem.2004.039149CrossRefPubMed

Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65:157–170. https://doi.org/10.1111/j.2042-7158.2012.01567.xCrossRefPubMed

Webb JL (1963) Effect of more than one inhibitor. Enzymes and metabolic inhibitors. Academic Press, New York

Werner TA, Tamkan-Olcek Y, Dizdar L, Riemer JC, Wolf A, Cupisti K, Verde PE, Knoefel WT, Krieg A (2016) Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma. Br J Cancer 114:427–434. https://doi.org/10.1038/bjc.2016.5CrossRefPubMedPubMedCentral

Werner TA, Dizdar L, Nolten I, Riemer JC, Mersch S, Schutte SC, Driemel C, Verde PE, Raba K, Topp SA, Schott M, Knoefel WT, Krieg A (2017) Survivin and XIAP—two potential biological targets in follicular thyroid carcinoma. Sci Rep 7:11383. https://doi.org/10.1038/s41598-017-11426-3CrossRefPubMedPubMedCentral

Wheatley SP, Altieri DC (2019) Survivin at a glance. J Cell Sci. https://doi.org/10.1242/jcs.223826CrossRefPubMedPubMedCentral

World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. https://doi.org/10.1001/jama.2013.281053CrossRef

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K (2012) Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun 425:711–716. https://doi.org/10.1016/j.bbrc.2012.07.103CrossRefPubMed

Zhang S, Wang X, Gu Z, Wang L (2016) Small molecule survivin inhibitor YM155 displays potent activity against human osteosarcoma cells. Cancer Invest 34:401–407. https://doi.org/10.1080/07357907.2016.1212205CrossRefPubMed

Title: Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
Authors: Christian Vay
Philipp M. Schlünder
Levent Dizdar
Irene Esposito
Markus P. H. Ghadimi
Wolfram T. Knoefel
Andreas Krieg
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keyword: Liposarcoma
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2022
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03871-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2022

Treatment and follow-up of rare testis tumours

Real-life drug–drug and herb–drug interactions in outpatients taking oral anticancer drugs: comparison with databases

Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report

Regulatory effects of lncRNAs and miRNAs on the crosstalk between autophagy and EMT in cancer: a new era for cancer treatment

Expressions and significances of CTSL, the target of COVID‐19 on GBM

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page